Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers
NCT04940533 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-01-20
Summary
This study aims to evaluate the pharmacokinetic changes during pregnancy, postpartum, and in breast milk in cystic fibrosis patients receiving a cystic fibrosis transmembrane conductance regulator (CTFR) modulator, including Elexacaftor, Tezacaftor, Ivacaftor, or Lumacaftor.
Conditions
- Cystic Fibrosis
- Pregnancy
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Jagadish Patil, MD · University of Minnesota
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2027-01-01
- Primary Completion
- 2028-07-01
- Completion
- 2028-07-01
Countries
- United States
Study Locations
More Related Trials
-
Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population
NCT07303621 ·Status: RECRUITING
-
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
NCT01807923 ·Status: COMPLETED ·Phase: PHASE3
-
Ensuring Access to Optimal Therapy in CF: The ENACT Study
NCT07148739 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring
NCT06797206 ·Status: RECRUITING
-
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
NCT01807949 ·Status: COMPLETED ·Phase: PHASE3
-
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
NCT06296394 ·Status: RECRUITING
-
Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)
NCT05526027 ·Status: UNKNOWN ·Phase: NA
-
Response to CFTR Modulators in CF Patients Under 18 Years
NCT04301856 ·Status: RECRUITING
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
NCT03601637 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del
NCT02653027 ·Status: WITHDRAWN ·Phase: NA
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis
NCT00004533 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT02797132 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT00457821 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
NCT05225805 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
NCT04568980 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
NCT02725567 ·Status: COMPLETED ·Phase: PHASE3
-
Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
NCT03061331 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
NCT02514473 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs
NCT04353752 ·Status: COMPLETED
-
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
NCT05530278 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients
NCT00792714 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
NCT03512119 ·Status: COMPLETED
-
Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
NCT00376428 ·Status: TERMINATED ·Phase: PHASE2
-
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
NCT01348204 ·Status: COMPLETED ·Phase: PHASE2